The core idea linking these three BioJapan 2025 keynotes is that bigger, better-connected research-and-manufacturing networks are now the decisive edge in health innovation. Fujifilm’s CDMO expansion, INSERM（Institut national de la santé et de la recherche médicale）’s international programs, and Institute of Science Tokyo’s “convergence science” model are three complementary ways to speed discoveries from lab … BioJapan 2025: Fujifilm Scales CDMO, Science Tokyo Advances Convergence Science and INSERM Coordinate Health R&D Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.